Skip to main content
Equibles
MGTX logo

MGTX · MeiraGTx Holdings plc

Track MGTX — free

Use MGTX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about MGTX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$14.54 -0.43 (-2.87%) At close · Aug 20
Market Cap
$1.44B
Shares
96.04M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$14.54 Open$14.93 Day$14.50–15.01 52W close$6.99–14.97 Avg vol 30d612K Short int3.9M · 4.1% float · 8.3d Short vol41% Last earningsApr 16, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 13

Up next

Next earnings call
Oct 2, 2026 Est · unconfirmed · in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 13, 2026

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Strong Buy Momentum Very Strong Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 14.9 · calm Equity put/call 0.52
Technical
price trend
Strong Buy
50 / 200-day cross No cross
Price vs 200-day avg +55%
above
Price vs 50-day avg +18%
above
RSI (14) 67
neutral
MACD trend Positive
52-week position 95%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +20%
trailing
6-month return +92%
trailing
YTD return +83%
this year
Relative strength +81%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $12 › 200d $9 — 50d above 200d
Institutional flow Accumulating
+17% holders QoQ · +39 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.06% of float · ▼ -7.5% MoM · 8.3 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
156 holders — near 3-yr high, broad support
Squeeze score 71
high risk · 0–100
Fundamentals
Strong
Revenue growth +145%
Y/Y
EPS growth +33%
Y/Y
Free cash flow $-50.2M
Valuation P/E 21.1
in line
Buyback $18.2M
authorized
Balance sheet $65.9M
net cash
Quant / Vol
risk profile
Very High
Volatility 60%
annualized · 1-yr
Max drawdown −25%
past year
ATR 4.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Buy
0 · 3 · 4
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+55% Bullish
Price vs 50-day avg
+18% Bullish
RSI (14)
67 Neutral
MACD trend
Positive Bullish
52-week position
95% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $12 › 200d $9 — 50d above 200d
Institutional flow Accumulating
+17% holders QoQ · +39 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
4.06% of float · ▼ -7.5% MoM · 8.3 days cover
Volume signal Reversal watch
High volume on a down day — possible exhaustion
Institution breadth Multi-yr high
156 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $7 Now $15 · 95% Range high $15
vs 200-day avg +55% vs 50-day avg +18%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MGTX
MeiraGTx Holdings plc
this stock
$1.44B +82.9% +144.6% 21.1 4.1%
ONC
BeOne Medicines Ltd.
 $557.05B +21.5% +22179.2% 856.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $136.93B +19.2% +46.2% 31.5 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $86.39B +7.1% +20.8% 20.8 3.3%
MRNA
Moderna, Inc.
 $69.62B +352.1% +4.3% — 12.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
156
% held
82.5%
Net QoQ
+11.8M sh
Top holder
Sanofi
Held Float
View
Held by Funds
Fund positions
38
View
Short & Settlement
Short Interest Falling
Shares short
3.9M
Days to cover
8.3d
Change
-317.7K sh
View
Short Volume
Short vol %
41%
As of
Aug 20, 2026
Short Total
View
Fails to Deliver
FTD shares
30.0K
Value
$373.2K
As of
Jul 15, 2026
View
Off-Exchange
Off-exchange %
49.5%
Week of
Jul 13, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$81.4M
Net income (FY)
$-114.2M
EPS diluted
$-1.42
View
Buybacks
Authorized
$18.2M
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 13, 2026
This year
15
View
Proposed Sales
Value
$859.3K
Shares
62.0K
Filed
Aug 18, 2026
View
Earnings & Events
Earnings Calls
Last call
Jun 4, 2026
View

Performance

5D 20D 120D MTD YTD
MGTX +14.8% +20.2% +92.3% +23.3% +82.9%
SPY -2.0% +3.3% +11.2% +2.1% +11.8%
vs SPY +16.7% +16.9% +81.2% +21.2% +71.1%

Capital returns

Buyback program · as of Dec 31, 2025
Authorized
$18.20M
Spent (derived)
—
Remaining
—

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 1735438 CUSIP G59665102 13F (30d) 146 filings 144 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)